GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Outcome of endoscopic retrograde cholangiopancreatography in patients with clinically defined decompensated liver cirrhosis
    Wiley ; 2018
    In:  Journal of Digestive Diseases Vol. 19, No. 10 ( 2018-10), p. 605-613
    Details
    In: Journal of Digestive Diseases, Wiley, Vol. 19, No. 10 ( 2018-10), p. 605-613
    Abstract: Decompensated liver cirrhosis (LC) can negatively affect the outcome of endoscopic retrograde cholangiopancreatography (ERCP). We aimed to compare the efficacy and safety of ERCP in patients with clinically defined compensated and decompensated LC. METHODS In a single tertiary hospital, 146 endoscopic sphincterotomy‐naive patients with LC who underwent ERCP between 2005 and 2016 were reviewed. Patients with LC who had experienced variceal bleeding, ascites or hepatic encephalopathy were included in the decompensated LC group. Cannulation, technical and clinical successes, and major post‐ERCP adverse events including bleeding, pancreatitis, cholangitis and perforation were compared between the two groups. RESULTS Patients were divided into compensated and decompensated LC groups. Their baseline characteristics were not different, except for comorbid malignancy (22.3 % vs 38.5%, P = 0.038) and preprocedural transfusion (7.4% vs 36.5%, P 〈 0.001). The cannulation (97,9% vs 94.2%, P = 0.348) and technical (95.7% vs 88.5% , P = 0.167) success rates were not different. The clinical success rate was lower in the decompensated LC group (95.7% and 78.8%, P = 0.003), mainly due to comorbid hepatobiliary malignancy. Post‐ERCP pancreatitis (6.4% vs 30.8%, P = 0.008) and cholangitis (18.1% vs 32.7%, P = 0.046) rates were higher in the decompensated LC group. CONCLUSIONS Despite lower clinical success rates due to comorbid hepatobiliary malignancy, ERCP in patients with decompensated LC is technically feasible. Because postprocedural cholangitis and pancreatitis are more frequent in patients with decompensated LC, greater procedural precautions are needed in these patients.
    Type of Medium: Online Resource
    ISSN: 1751-2972 , 1751-2980
    URL: Issue
    URL: Article
    DOI: 10.1111/cdd.2018.19.issue-10
    DOI: 10.1111/1751-2980.12661
    Language: English
    Publisher: Wiley
    Publication Date: 2018
    detail.hit.zdb_id: 2317117-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Clinical Impact of Unexpected Para-Aortic Lymph Node Metastasis in Surgery for Resectable Pancreatic Cancer
    MDPI AG ; 2021
    In:  Cancers Vol. 13, No. 17 ( 2021-09-03), p. 4454-
    Details
    In: Cancers, MDPI AG, Vol. 13, No. 17 ( 2021-09-03), p. 4454-
    Abstract: Radiologically identified para-aortic lymph node (PALN) metastasis is contraindicated for pancreatic cancer (PC) surgery. There is no clinical consensus for unexpected intraoperative PALN enlargement. To analyze the prognostic role of unexpected PALN enlargement in resectable PC, we retrospectively reviewed data of 1953 PC patients in a single tertiary center. Patients with unexpected intraoperative PALN enlargement (group A1, negative pathology, n = 59; group A2, positive pathology, n = 13) showed median overall survival (OS) of 24.6 (95% CI: 15.2–33.2) and 13.0 (95% CI: 4.9–19.7) months, respectively. Patients with radiological PALN metastasis without other metastases (group B, n = 91) showed median OS of 8.6 months (95% CI: 7.4–11.6). Compared with group A1, groups A2 and B had hazard ratios (HRs) of 2.79 (95% CI, 1.4–5.7) and 2.67 (95% CI: 1.8–4.0), respectively. Compared with group A2, group B had HR of 0.96 (95% CI: 0.5–1.9). Multivariable analysis also showed positive PALN as a negative prognostic factor (HR 2.57, 95% CI: 1.2–5.3), whereas positive regional lymph node did not (HR 1.32 95% CI: 0.8–2.3). Thus, unexpected malignant PALN has a negative prognostic impact comparable to radiological PALN metastasis. This results suggests prompt pathologic evaluation for unexpected PALN enlargements is needed and on-site modification of surgical strategy would be considered.
    Type of Medium: Online Resource
    ISSN: 2072-6694
    URL: Article
    DOI: 10.3390/cancers13174454
    Language: English
    Publisher: MDPI AG
    Publication Date: 2021
    detail.hit.zdb_id: 2527080-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Gemcitabine Plus Cisplatin Chemotherapy Prolongs the Survival in Advanced Hilar Cholangiocarcinoma : A Large Multicenter Study
    Ovid Technologies (Wolters Kluwer Health) ; 2020
    In:  American Journal of Clinical Oncology Vol. 43, No. 6 ( 2020-06), p. 422-427
    Details
    In: American Journal of Clinical Oncology, Ovid Technologies (Wolters Kluwer Health), Vol. 43, No. 6 ( 2020-06), p. 422-427
    Abstract: Gemcitabine plus cisplatin (GC) is recommended as first-line treatment for advanced cholangiocarcinoma. We investigated the impact of GC in patients with unresectable hilar cholangiocarcinoma (HC) based on the time taken for effective biliary drainage (EBD). Materials and Methods: We retrospectively enrolled 113 patients with unresectable HC. Thirty-nine and 74 patients received GC chemotherapy and best supportive care (BSC), respectively. EBD was defined as a reduction in total bilirubin 〉 50% or to a value 〈 2 mg/dL after the drainage procedure. Early EBD (eEBD) and delayed EBD (dEBD) were separated by 2 weeks. Overall survival (OS) was estimated. Results: The GC group showed a significantly longer median OS than the BSC group (12.8 vs. 6.1 mo; P 〈 0.001). Moreover, the eEBD group experienced a significantly longer OS than the dEBD group (8.2 vs. 4.3 mo; P 〈 0.001). GC led to improved OS in the eEBD (12.8 vs. 6.8 mo; P =0.003) and dEBD (12.2 vs. 3.4 mo; P =0.009) groups. In multivariate analysis, dEBD (adjusted hazard ratio [aHR], 1.785; 95% confidence interval [CI] , 1.183-2.691; P =0.006), BSC (aHR, 2.409; 95% CI, 1.579-3.675; P 〈 0.001), and an ECOG status ≥2 (aHR, 3.721; 95% CI, 2.093-6.615; P 〈 0.001) were associated with poor prognosis. In GC group, the older (70 y and above) patients did not have a higher risk of death than younger patients. Conclusions: GC prolongs the survival of patients with unresectable HC, even those with dEBD or elderly.
    Type of Medium: Online Resource
    ISSN: 0277-3732
    URL: Article
    DOI: 10.1097/COC.0000000000000682
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2020
    detail.hit.zdb_id: 2043067-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Percutaneous transhepatic versus EUS-guided gallbladder drainage for malignant cystic duct obstruction
    Elsevier BV ; 2017
    In:  Gastrointestinal Endoscopy Vol. 85, No. 2 ( 2017-02), p. 357-364
    Details
    In: Gastrointestinal Endoscopy, Elsevier BV, Vol. 85, No. 2 ( 2017-02), p. 357-364
    Type of Medium: Online Resource
    ISSN: 0016-5107
    URL: Article
    DOI: 10.1016/j.gie.2016.07.067
    RVK:
    XA 44545
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2017
    detail.hit.zdb_id: 2006253-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Management of recurrent pancreatic cancer after surgical resection: Systematic review, evidence mapping, and meta-analysis.
    American Society of Clinical Oncology (ASCO) ; 2017
    In:  Journal of Clinical Oncology Vol. 35, No. 4_suppl ( 2017-02-01), p. 448-448
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 35, No. 4_suppl ( 2017-02-01), p. 448-448
    Abstract: 448 Background: Although almost patients with surgically resected pancreatic cancer (PC) experience recurrence, the optimal treatment option of recurrent PC is still unclear. Numerous studies have been reported about this issue, but all the scattered evidences are too small and heterogeneous to reach a conclusion. The aim of this systematic review is to perform ‘evidence mapping’ and subgroup meta-analysis. Methods: In regards to local recurrence and metastatic recurrence respectively, four treatment options including re-operation (ReOP), chemotherapy (CTx), radiotherapy (RT), best supportive care (BSC) were searched from Medline, Embase, Cochrane library, Scopus and Web of Science from 1976 to April 30, 2016. To visualize the mapping of evidence, we established a web-based mapping tool ( http://plotting-e-map.com ) and used it. In the treatment options with selected study types, subgroup meta-analyses were conducted using overall survival as a primary endpoint. Results: Among detected 12,040 studies, a total of 162 studies were included. In locally recurrent PC, overall 126 studies (39 of ReOP, 40 of CTx, 37 of RT, and 10 of BSC) were included. Median overall survival (OS) of each treatment option was 16.1 months (95% CI 4.9–22.1, I 2 52%) for ReOP, 14.9 month (95% CI 7.5–18.9, I 2 63%) for CTx, 13.8 months (95% CI 5.6–17.0, I 2 59%) for RT. In metastatic recurred PC, overall 36 studies (10 of ReOP, 22 of CTx, no RT, 4 of BSC) were included. Median OS’s were 8.3 months (95% CI 3.6–11.2, I 2 56%) for Re-OP, and 6.8 months (95% CI 4.1–9.5, I 2 33%) for CTx. Conclusions: During recent 40 years, evidences showed that re-operation for highly selected patients with locally and metastatic recurrent PC could be a considerable therapeutic option. However, since the heterogeneity among the studies is relatively high, more prospective and comparative studies about re-operation with multimodality treatment are needed.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2017.35.4_suppl.448
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2017
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Abstract 248: A novel PubMed visualizer using human-computer interaction technology: EEEvis.com
    American Association for Cancer Research (AACR) ; 2021
    In:  Cancer Research Vol. 81, No. 13_Supplement ( 2021-07-01), p. 248-248
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 81, No. 13_Supplement ( 2021-07-01), p. 248-248
    Abstract: PubMed is the most widely used database and search-engine in biomedical and healthcare field. It has evolved more powerfully using Best Match algorithm. However, users still have several difficulties to ‘catch' their target papers in limited time, which fundamentally originates from the conventional two-dimensional ‘top-down' display method of search results. We conducted a survey for 76 medical experts (including oncologists, surgeons, gastroenterologists, psychiatrists, et al) about their behaviors and difficulties in using PubMed. The most common ‘unmet needs' of users were (1) the rank of citation counts or impact factors, (2) more three-dimensional and interactive display of search results, and (3) author rank and network. Reflecting the results above, we developed a novel PubMed visualizing program, EEEvis version 1.0 (medical and healthcare evidence visualizer), and launched it on www.EEEvis.com. The basic operating principle of EEEvis version 1.0 is to visualize the metadata of PubMed and PubTator (a web-based text mining-tool) using (1) advanced filter tools, (2) a scatter & box plot using citation counts over years, (3) an author map reflecting the ranks and networks, and (4) a reinforced search list (Table 1). All the data crawling is based on the API (application programming interface) of PubMed and PubTator. To computing and visualizing the crawled metadata, we constructed two servers; a hidden station server and an open UI (user interface) server. In the interim result of our ongoing pilot study in searching oncology-related literatures, the two quantitative factors including (1) time to ‘catch' the target paper and (2) success rate finding the required paper showed significant improvement. Other qualitative factors including (3) user convenience, (4) interactivity, and (5) willingness to use EEEvis next time showed good results. Now we are developing EEEvis version 2.0 using text-mining technology and applying multiple patents for this program. Comparison between EEEvis and PubMedProgramsEEEvisPubMedFilter sectionBy article typeYesYesBy publication yearYesYesBy citation count of paperYesNoBy impact factor of journalYesNoInteraction section using Brushing & Linking techniqueScatter plot of citation counts by yearYesNo(with box plot of citation counts by year)YesNoMap of author networkYesNoList sectionSort by best matchYesYesSort by most recentYesYesSort by citation countYesNoSort by author or journalNoYesCitation count of each paperYesNoImpact factor of each journalYesNoPubTator informationYesNoData crawlingHow to crawl results from Pubmed serverIndirect using APIDirectLimit of result numbers10,000 (best matched)NoneUser experience in searching cancer-related keywords in pilot study (ongoing)Time to display results after entering keywordsNot inferiorPromptTime from visualizing results to finding the required paperSuperior(= faster)InferiorSuccess rate of finding the required paper after visualizing the resultsSuperiorInferior Citation Format: Jong-chan Lee, Brian J. Lee, Hyunjoo Song, Changhee Park, Chan-Young Ock, Yuna Youn, Hyojae Sung, Sungjin Woo, Jaihwan Kim, Jin-Hyeok Hwang. A novel PubMed visualizer using human-computer interaction technology: EEEvis.com [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 248.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/1538-7445.AM2021-248
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2021
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Risk Factors for Gallstone Formation in Resected Gastric Cancer Patients
    Ovid Technologies (Wolters Kluwer Health) ; 2016
    In:  Medicine Vol. 95, No. 15 ( 2016-04), p. e3157-
    Details
    In: Medicine, Ovid Technologies (Wolters Kluwer Health), Vol. 95, No. 15 ( 2016-04), p. e3157-
    Type of Medium: Online Resource
    ISSN: 0025-7974
    URL: Article
    DOI: 10.1097/MD.0000000000003157
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2016
    detail.hit.zdb_id: 2049818-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer : A single center experience
    Ovid Technologies (Wolters Kluwer Health) ; 2018
    In:  Medicine Vol. 97, No. 50 ( 2018-12), p. e13592-
    Details
    In: Medicine, Ovid Technologies (Wolters Kluwer Health), Vol. 97, No. 50 ( 2018-12), p. e13592-
    Abstract: Systemic chemotherapy or chemoradiotherapy is the initial primary option for patients with locally advanced pancreatic cancer (LAPC). This study analyzed the effect of FOLFIRINOX and assessed the factors influencing conversion to surgical resectability for LAPC. Sixty-four patients with LAPC who received FOLFIRINOX as initial chemotherapy were enrolled retrospectively. Demographic characteristics, tumor status, interval/dosage/cumulative relative dose intensity (cRDI) of FOLFIRINOX, conversion to resection, and clinical outcomes were reviewed and factors associated with conversion to resectability after FOLFIRINOX were analyzed. After administration of FOLFIRINOX (median 9 cycles, 70% of cRDI), the median patient overall survival (OS) was 17.0 months. Fifteen of 64 patients underwent surgery and R0 resection was achieved in 11 patients. During a median follow-up time of 9.4 months after resection, cumulative recurrence rate was 28.5% at 18 months after resection. The estimated median OS was significantly longer for the resected group ( 〉 40 months vs 13 months). There were no statistical differences between the resected and non-resected groups in terms of baseline characteristics, tumor status and hematologic adverse effects. The patients who received standard dose of FOLFIRINOX had higher probability of subsequent resection compared with patients who received reduced dose, although cRDIs did not differ between groups. FOLFIRINOX is an active regimen in patients with LAPC, given acceptable resection rates and promising R0 resection rates. Additionally, our data demonstrate it is advantageous for obtaining resectability to administer FOLFIRINOX without dose reduction.
    Type of Medium: Online Resource
    ISSN: 0025-7974 , 1536-5964
    URL: Article
    DOI: 10.1097/MD.0000000000013592
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2018
    detail.hit.zdb_id: 2049818-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study
    Springer Science and Business Media LLC ; 2022
    In:  European Radiology Vol. 32, No. 6 ( 2022-06), p. 3799-3807
    Details
    In: European Radiology, Springer Science and Business Media LLC, Vol. 32, No. 6 ( 2022-06), p. 3799-3807
    Type of Medium: Online Resource
    ISSN: 1432-1084
    URL: Article
    DOI: 10.1007/s00330-021-08494-5
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2022
    detail.hit.zdb_id: 1472718-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    Efficacy improvement in searching MEDLINE database using a novel PubMed visual analytic system: EEEvis
    Public Library of Science (PLoS) ; 2023
    In:  PLOS ONE Vol. 18, No. 2 ( 2023-2-9), p. e0281422-
    Details
    In: PLOS ONE, Public Library of Science (PLoS), Vol. 18, No. 2 ( 2023-2-9), p. e0281422-
    Abstract: PubMed is the most extensively used database and search engine in the biomedical and healthcare fields. However, users could experience several difficulties in acquiring their target papers facing massive numbers of search results, especially in their unfamiliar fields. Therefore, we developed a novel user interface for PubMed and conducted three steps of study: step A, a preliminary user survey with 76 medical experts regarding the current usability for the biomedical literature search task at PubMed; step B is implementing EEEvis, a novel interactive visual analytic system for the search task; step C, a randomized user study comparing PubMed and EEEvis. First, we conducted a Google survey of 76 medical experts regarding the unmet needs of PubMed and the user requirements for a novel search interface. According to the data of preliminary Google survey, we implemented a novel interactive visual analytic system for biomedical literature search. This EEEvis provides enhanced literature data analysis functions including (1) an overview of the bibliographic features including publication date, citation count, and impact factors, (2) an overview of the co-authorship network, and (3) interactive sorting, filtering, and highlighting. In the randomized user study of 24 medical experts, the search speed of EEEvis was not inferior to PubMed in the time to reach the first article (median difference 3 sec, 95% CI -2.1 to 8.5, P = 0.535) nor in the search completion time (median difference 8 sec, 95% CI -4.7 to 19.1, P = 0.771). However, 22 participants (91.7%) responded that they are willing to use EEEvis as their first choice for a biomedical literature search task, and 21 participants (87.5%) answered the bibliographic sorting and filtering functionalities of EEEvis as a major advantage. EEEvis could be a supplementary interface for PubMed that can enhance the user experience in the search for biomedical literature.
    Type of Medium: Online Resource
    ISSN: 1932-6203
    URL: Article
    URL: Article
    URL: Article
    URL: Article
    URL: Article
    URL: Article
    URL: Article
    URL: Article
    URL: Article
    URL: Article
    URL: Article
    URL: Article
    URL: Article
    URL: Article
    URL: Article
    URL: Article
    DOI: 10.1371/journal.pone.0281422
    DOI: 10.1371/journal.pone.0281422.g001
    DOI: 10.1371/journal.pone.0281422.g002
    DOI: 10.1371/journal.pone.0281422.g003
    DOI: 10.1371/journal.pone.0281422.g004
    DOI: 10.1371/journal.pone.0281422.g005
    DOI: 10.1371/journal.pone.0281422.g006
    DOI: 10.1371/journal.pone.0281422.t001
    DOI: 10.1371/journal.pone.0281422.t002
    DOI: 10.1371/journal.pone.0281422.t003
    DOI: 10.1371/journal.pone.0281422.t004
    DOI: 10.1371/journal.pone.0281422.s001
    DOI: 10.1371/journal.pone.0281422.s002
    DOI: 10.1371/journal.pone.0281422.s003
    DOI: 10.1371/journal.pone.0281422.s004
    DOI: 10.1371/journal.pone.0281422.s005
    Language: English
    Publisher: Public Library of Science (PLoS)
    Publication Date: 2023
    detail.hit.zdb_id: 2267670-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...